Sathish Kumar Krishnan, MD
Pulmonary Disease · Indianapolis, INNPI 1508121492
Payments from drug & device makers
Across 187 payments — averaging $27.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$2K
- GSK$441
- Boehringer Ingelheim$336
- Jazz Pharmaceuticals Inc.$276
- Grifols USA, LLC$238
- Boston Scientific$207
- plus $2K from 30 others
What the payments were for
- Travel & lodging$1,48529%
- Food & beverage$3,70671%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 15 | $1,595 |
| GSK | 29 | $441 |
| Boehringer Ingelheim | 21 | $336 |
| Jazz Pharmaceuticals Inc. | 7 | $276 |
| Grifols USA, LLC | 5 | $238 |
| Boston Scientific | 1 | $207 |
| Pulmonx Corporation | 4 | $166 |
| AbbVie | 6 | $157 |
| Sunovion Pharmaceuticals Inc. | 11 | $156 |
| United Therapeutics Corporation | 2 | $152 |
| AstraZeneca | 9 | $144 |
| Regeneron Healthcare Solutions, Inc. | 5 | $123 |
| Mylan Specialty L.p. | 6 | $102 |
| Pfizer | 7 | $101 |
| Merck | 3 | $100 |
| Sanofi | 6 | $98 |
| Actelion Pharmaceuticals US, Inc. | 5 | $97 |
| Genentech USA, Inc. | 7 | $90 |
| Paratek Pharmaceuticals, Inc. | 4 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $57 |
| Electromed, Inc. | 6 | $56 |
| Gilead | 4 | $51 |
| Harmony Biosciences LLC | 2 | $48 |
| Johnson & Johnson | 2 | $37 |
| Insmed, Inc. | 2 | $36 |
| Resmed Corp | 2 | $34 |
| Advanced Respiratory, Inc | 2 | $31 |
| Novartis | 2 | $30 |
| Inspire Medical Systems, Inc. | 2 | $30 |
| Viatris Specialty LLC | 2 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Amgen | 1 | $25 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $24 |
| Philips North America LLC | 1 | $21 |
| Bayer | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,204 in reported general payments places this provider in the 65th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 551 | $484,290 |
| OfevNintedanib Esylate | 27 | $351,637 |
| Spiriva RespimatTiotropium Bromide | 159 | $120,182 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 182 | $114,647 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 147 | $85,052 |
| Breo ElliptaFluticasone/Vilanterol | 138 | $74,034 |
| Dupixent SyringeDupilumab | 14 | $61,809 |
| Dupixent PenDupilumab | 14 | $54,502 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 68 | $47,664 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 69 | $39,897 |
| EliquisApixaban | 17 | $24,426 |
| SymbicortBudesonide/Formoterol Fumarate | 65 | $20,715 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 58 | $19,022 |
| Pirfenidone | 12 | $18,277 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 612 | $17,268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $441 | $663,428868 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $336 | $626,363437 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Airsupra | $144 | $73,445144 claims |
| PfizerEliquis | $101 | $24,42617 claims |
| MerckDulera | $100 | $10,42427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Indianapolis
- Cynthia BrownIndianapolis$7.3M
- Roberto MachadoIndianapolis$219K
- Michael DuncanIndianapolis$146K
- Gary ZalogaIndianapolis$79K
- Abboud KawakIndianapolis$68K
- Ryan LogueIndianapolis$30K
- George RubeizIndianapolis$24K
- Clare ProhaskaIndianapolis$20K
- Rajat NarangIndianapolis$17K
- Marcus TielkerIndianapolis$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.